Abeona Therapeutics Inc. Stock News

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that researchers from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospi

Investment Analysts’ updated eps estimates for Tuesday, February 11th: Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The

The coronavirus outbreak from Wuhan has hit Hong Kong stocks hard as they resume trade. We won't know the impact on mainland listings until next week at the earliest.

NEW YORK and CLEVELAND, Jan. 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the.

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation

Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier...

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has received Institutional Review Board (IRB) approval from Stanford University to commence

Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also

NEW YORK, NY / ACCESSWIRE / January 2, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or "the ...

The ability to modify genes may be one of the most promising disruptive technologies there is today. As the general public learns about the potential of gene editing, retail investors will be looki

Thousands of kind-hearted well-wishers were moved by the challenges faced by Rhys Williams, who lives with rare skin condition epidermolysis bullosa.

Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in

Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell therapies to treat hematological malignancies, raised $42m

08 May 2018 - Market at Midday: ASX200 back at 10-year highs. Retail trade remained steady in March in seasonally adjusted terms, disappointing economists who expected a rise of 0.3 per cent. Federal

Experts comment on manufacturing of CAR-T